{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:48:18Z","timestamp":1792064898722,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16554-6","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:06:16Z","timestamp":1784549176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemotherapy-induced toxicities and associated factors among patients with gastrointestinal tract cancer at two tertiary care hospitals in Ethiopia: a prospective observational study"],"prefix":"10.1186","volume":"26","author":[{"given":"Samson Fisseha","family":"Melaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyahil Alebachew","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atalay Mulu","family":"Fentie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alemseged Beyene","family":"Berha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"16554_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","DOI":"10.3322\/caac.21492"},{"key":"16554_CR2","doi-asserted-by":"crossref","unstructured":"Zingeta GT, Worku YT, Getachew A, Feyisa JD, Furgassa H, Belay W, Mengesha T, Jemal A, Assefa M. Clinical presentation, treatment patterns, and outcomes of colorectal cancer patients at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia: A prospective cohort study. Cancer Reports. 2023;6(9):e1869.","DOI":"10.1002\/cnr2.1869"},{"key":"16554_CR3","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S116924","author":"SA Belachew","year":"2016","unstructured":"Belachew SA, Erku DA, Mekuria AB, Gebresillassie BM. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study. Drug Healthc Patient Saf. 2016. https:\/\/doi.org\/10.2147\/DHPS.S116924.","journal-title":"Drug Healthc Patient Saf"},{"key":"16554_CR4","doi-asserted-by":"crossref","unstructured":"Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335\u201349.e315.","DOI":"10.1053\/j.gastro.2020.02.068"},{"key":"16554_CR5","first-page":"1913","volume":"16","author":"T Koca","year":"2015","unstructured":"Koca T, Arslan D, Basaran H, Cerkesli AK, Sezen D, Koca O, et al. Dietary and Demographical Risk Factors for Oesophageal Squamous Cell Carcinoma in the Eastern Anatolian Region of Turkey Where Upper Gastrointestinal Cancers are Endemic. 2015;16:1913\u20137.","journal-title":"Dietary and Demographical Risk Factors for Oesophageal Squamous Cell Carcinoma in the Eastern Anatolian Region of Turkey Where Upper Gastrointestinal Cancers are Endemic"},{"key":"16554_CR6","doi-asserted-by":"crossref","unstructured":"Hong MZ, Li JM, Chen ZJ, Lin XY, Pan JS, Gong LL. Global burden of major gastrointestinal cancers and its association with socioeconomics, 1990-2019. Front Oncol. 2022;12:942035.","DOI":"10.3389\/fonc.2022.942035"},{"issue":"5","key":"16554_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.23950\/jcmk\/13691","volume":"20","author":"S Goktas","year":"2023","unstructured":"Goktas S, Gezginci E. Identifying potential risk factors associated with gastrointestinal tract cancers: A case-control study in Turkey. J Clin Med Kazakhstan. 2023;20(5):17\u201321.","journal-title":"J Clin Med Kazakhstan"},{"issue":"1","key":"16554_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-022-02275-0","volume":"22","author":"AF Awedew","year":"2022","unstructured":"Awedew AF, Asefa Z, Belay WB. Burden and trend of colorectal cancer in 54 countries of Africa 2010\u20132019: a systematic examination for Global Burden of Disease. BMC Gastroenterol. 2022;22(1):1\u201312.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"16554_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2021-052376","volume":"12","author":"N Arhin","year":"2022","unstructured":"Arhin N, Ssentongo P, Taylor M, Olecki EJ, Pameijer C, Shen C, et al. Age-standardised incidence rate and epidemiology of colorectal cancer in Africa: a systematic review and meta-analysis. BMJ Open. 2022;12(1):1\u20137.","journal-title":"BMJ Open"},{"key":"16554_CR10","doi-asserted-by":"crossref","unstructured":"Somi MH, Dolatkhah R, Sepahi S, Belalzadeh M, Naghashi S, Asghari Jafarabadi M. A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry. BMC cancer. 2019;19(1):782.","DOI":"10.1186\/s12885-019-6008-3"},{"issue":"3","key":"16554_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3892\/ol.2011.260","volume":"2","author":"Y Kuboki","year":"2011","unstructured":"Kuboki Y, Mizunuma N, Ozaka M, Ogura M, Suenaga M, Shinozaki E, et al. Grade 3\/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer. Oncol Lett. 2011;2(3):493\u20138.","journal-title":"Oncol Lett"},{"issue":"9","key":"16554_CR12","first-page":"7159","volume":"30","author":"A Donkor","year":"2022","unstructured":"Donkor A, Atuwo-Ampoh VD, Yakanu F, Torgbenu E, Ameyaw EK, Kitson-Mills D, et al. Khader OJSCiC: Financial toxicity of cancer care in low-and middle-income countries: a systematic review and meta-analysis. 2022;30(9):7159\u201390.","journal-title":"Khader OJSCiC: Financial toxicity of cancer care in low-and middle-income countries: a systematic review and meta-analysis"},{"key":"16554_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e18849","volume-title":"Cost-effectiveness of adjuvant chemotherapy for stage III colon cancer in the South African public healthcare setting","author":"YS Pumpalova","year":"2021","unstructured":"Pumpalova YS, Rogers AM, Tan SX, Herbst C-L, Ruff P, Neugut AI, et al. Cost-effectiveness of adjuvant chemotherapy for stage III colon cancer in the South African public healthcare setting. Wolters Kluwer Health; 2021."},{"key":"16554_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17128-9","author":"AF Awedew","year":"2010","unstructured":"Awedew AF, Asefa Z, Belay WB. National burden and trend of cancer in Ethiopia, 2010\u20132019: a systemic analysis for Global burden of disease study. Sci Rep. 2010. https:\/\/doi.org\/10.1038\/s41598-022-17128-9.","journal-title":"Sci Rep"},{"issue":"9","key":"16554_CR15","first-page":"1","volume":"6","author":"GT Zingeta","year":"2023","unstructured":"Zingeta GT, Worku YT, Getachew A, Feyisa JD, Furgassa H, Belay W, et al. Clinical presentation, treatment patterns, and outcomes of colorectal cancer patients at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia: a prospective cohort study. Cancer Rep. 2023;6(9):1\u201314.","journal-title":"Cancer Rep"},{"key":"16554_CR16","doi-asserted-by":"publisher","unstructured":"T Michnevich Y Pan A Hendi K Oechsle A Stein Y Nestoriuc 2022 Preventing adverse events of chemotherapy for gastrointestinal cancer by educating patients about the nocebo effect: a randomized controlled trial BMC Cancer 1https:\/\/doi.org\/10.1186\/s12885-022-10089-2","DOI":"10.1186\/s12885-022-10089-2"},{"key":"16554_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/BCTT.S289014","volume":"13","author":"DA Gadisa","year":"2021","unstructured":"Gadisa DA, Wang SH, Yimer G. The impact of AC and AC-T chemotherapy\u2019s toxicities on quality of life among women with breast cancer in Ethiopia: a prospective patient-reported outcomes study. Breast Cancer Targets Ther. 2021;13:107\u201332.","journal-title":"Breast Cancer Targets Ther"},{"key":"16554_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2636514","author":"DA Gadisa","year":"2020","unstructured":"Gadisa DA, Assefa M, Tefera GM, Yimer G. Patterns of anthracycline\u2010based chemotherapy\u2010induced adverse drug reactions and their impact on relative dose intensity among women with breast cancer in Ethiopia: a prospective observational study. J Oncol. 2020. https:\/\/doi.org\/10.1155\/2020\/2636514.","journal-title":"J Oncol"},{"issue":"5","key":"16554_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00520-010-0816-y","volume":"18","author":"M Aapro","year":"2010","unstructured":"Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer. 2010;18(5):529\u201341.","journal-title":"Support Care Cancer"},{"key":"16554_CR20","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S386181","author":"M Dessalegn","year":"2023","unstructured":"Dessalegn M, Fantahun M, Yesufe AA, Hussein M, Tsegaye A. Chemotherapy induced neutropenia, febrile-neutropenia and determinants among solid cancer patients attending oncology unit of a tertiary care teaching hospital in Ethiopia. Cancer Manag Res. 2023. https:\/\/doi.org\/10.2147\/CMAR.S386181.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"16554_CR21","first-page":"3336","volume":"14","author":"K Xi","year":"2024","unstructured":"Xi K, Jingping L, Yaqing L, Xinyuan Y, Hui L, Mei Y, et al. Analysis of the factors influencing moderate to poor performance status in patients with cancer after chemotherapy: a cross-sectional study comparing three models. 2024;14(1):3336.","journal-title":"Analysis of the factors influencing moderate to poor performance status in patients with cancer after chemotherapy: a cross-sectional study comparing three models"},{"issue":"2","key":"16554_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"16554_CR23","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population\u2010based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"16554_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201356.","journal-title":"Am J Clin Oncol"},{"key":"16554_CR25","doi-asserted-by":"crossref","unstructured":"Tola WO, Melaku T, Fufa D, Sheleme T. Adverse drug events and contributing factors among pediatric cancer patients at Jimma University medical center, Southwest Ethiopia. BMC Pediatr. 2023;23(1):77.","DOI":"10.1186\/s12887-023-03891-9"},{"key":"16554_CR26","unstructured":"DiPiro JT, Talbert RL, Yee G, Matzke GR, Wells BG, Posey LM. Pharmacotherapy A: A pathophysiologic approach. In: The McGraw-Hills Companies, United States of America; 2008."},{"issue":"2","key":"16554_CR27","first-page":"107","volume":"1","author":"A Prasad","year":"2013","unstructured":"Prasad A, Datta P, Bhattacharya J, Pattanayak C, Chauhan A, Panda PJJP. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Eastern India. 2013;1(2):107.","journal-title":"Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Eastern India"},{"issue":"4","key":"16554_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.31662\/jmaj.2021-0015","volume":"5","author":"R Tamang","year":"2022","unstructured":"Tamang R, Bharati L, Khatiwada AP, Ozaki A, Shrestha S. Pattern of adverse drug reactions associated with the use of anticancer drugs in an oncology-based hospital of Nepal. JMA J. 2022;5(4):416\u201326.","journal-title":"JMA J"},{"issue":"9","key":"16554_CR29","first-page":"e968","volume":"24","author":"AH Lavan","year":"2019","unstructured":"Lavan AH, O\u2019Mahony D, Buckley M. O\u2019Mahony D. Gallagher PJTo: Adverse drug reactions in an oncological population: prevalence, predictability, and preventability. 2019;24(9):e968\u201377.","journal-title":"Gallagher PJTo: Adverse drug reactions in an oncological population: prevalence, predictability, and preventability"},{"issue":"1","key":"16554_CR30","first-page":"65","volume":"30","author":"Z Aoullay","year":"2020","unstructured":"Aoullay Z, Slaoui M, Razine R, Er-Raki A, Meddah B, Cherrah Y. Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients. Ethiop J Health Sci. 2020;30(1):65\u201374.","journal-title":"Ethiop J Health Sci"},{"issue":"6","key":"16554_CR31","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3748\/wjg.v20.i6.1565","volume":"20","author":"L Rambach","year":"2014","unstructured":"Rambach L, Bertaut A, Vincent J, Lorgis V, Ladoire S, Ghiringhelli F. Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. World J Gastroenterol. 2014;20(6):1565\u201373.","journal-title":"World J Gastroenterol"},{"key":"16554_CR32","doi-asserted-by":"crossref","unstructured":"Iannantuono G, Giovagnoli T, Mastrantoni L, Gyawali B, Floudas C, Sganga S, Giannarelli D, Filetti M, Spinazzola A, Bianco FLJEo: Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression. 2026, 11(2):106065.","DOI":"10.1016\/j.esmoop.2026.106065"},{"issue":"4","key":"16554_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.18203\/2349-3933.ijam20230702","volume":"10","author":"AA Naqash","year":"2023","unstructured":"Naqash AA, Nayak BA, Wani SB, Teli MA. Clinical profile and treatment outcome in gastrointestinal cancer patients: a single-center experience in Kashmir valley, India. International Journal of Advances in Medicine. 2023;10(4):281\u20135.","journal-title":"International Journal of Advances in Medicine"},{"issue":"5","key":"16554_CR34","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.21608\/ejhm.2020.123478","volume":"81","author":"AM Sarhan","year":"2020","unstructured":"Sarhan AM, Soliman MA, El-Sebai EA, El-Demery MMA. Different treatment modalities of colo-rectal cancer (Retrospective study). Egyptian Journal of Hospital Medicine. 2020;81(5):1953\u20137.","journal-title":"Egyptian Journal of Hospital Medicine"},{"key":"16554_CR35","doi-asserted-by":"crossref","unstructured":"Wahlang JB, Laishram PD, Brahma DK, Sarkar C, Lahon J, Nongkynrih BS. Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Ther Adv Drug Saf. 2017;8(2):61\u20136.","DOI":"10.1177\/2042098616672572"},{"issue":"11","key":"16554_CR36","doi-asserted-by":"publisher","first-page":"8269","DOI":"10.3390\/curroncol29110653","volume":"29","author":"SM Nguyen","year":"2022","unstructured":"Nguyen SM, Pham AT, Nguyen LM, Cai H, Tran TV, Shu XO, et al. Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam. Curr Oncol. 2022;29(11):8269\u201384.","journal-title":"Curr Oncol"},{"key":"16554_CR37","doi-asserted-by":"crossref","unstructured":"Negarandeh R, Salehifar E, Saghafi F, Jalali H, Janbabaei G, Abdhaghighi MJ, Nosrati A. Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC cancer. 2020;20(1):560.","DOI":"10.1186\/s12885-020-06904-3"},{"key":"16554_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.38","volume-title":"Chemotherapy-induced neutropenia with FOLFOX in the adjuvant treatment of colorectal cancer","author":"J Gotfrit","year":"2020","unstructured":"Gotfrit J, Marginean H, Maroun JA, Trincao-Batra S, Asmis TR, Vickers MM, et al. Chemotherapy-induced neutropenia with FOLFOX in the adjuvant treatment of colorectal cancer. In.: American Society of Clinical Oncology; 2020."},{"key":"16554_CR39","volume":"4","author":"A Digklia","year":"2024","unstructured":"Digklia A, Arnold D. Voutsadakis IJEGO: Second-line FOLFOX chemotherapy for patients with advanced biliary tract cancers pretreated with cisplatin\/gemcitabine: a systematic review and meta-analysis. 2024;4:100055.","journal-title":"Voutsadakis IJEGO: Second-line FOLFOX chemotherapy for patients with advanced biliary tract cancers pretreated with cisplatin\/gemcitabine: a systematic review and meta-analysis"},{"issue":"2","key":"16554_CR40","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/cam4.200","volume":"3","author":"E Culakova","year":"2014","unstructured":"Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, et al. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014;3(2):434\u201344.","journal-title":"Cancer Med"},{"issue":"1","key":"16554_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/0971-5851.177015","volume":"37","author":"D Chopra","year":"2016","unstructured":"Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Indian J Med Paediatr Oncol. 2016;37(1):42\u20136.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"February","key":"16554_CR42","first-page":"1","volume":"10","author":"HY Hassen","year":"2021","unstructured":"Hassen HY, Teka MA, Addisse A. Survival Status of Esophageal Cancer Patients and its Determinants in Ethiopia\u202f: A Facility Based Retrospective Cohort Study. 2021;10(February):1\u20139.","journal-title":"Survival Status of Esophageal Cancer Patients and its Determinants in Ethiopia : A Facility Based Retrospective Cohort Study"},{"issue":"2","key":"16554_CR43","first-page":"109","volume":"6","author":"HD Manohar","year":"2015","unstructured":"Manohar HD, Bairy KL, Thomas J. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India. 2015;6(2):109\u201315.","journal-title":"Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India"},{"issue":"9","key":"16554_CR44","first-page":"1061","volume":"25","author":"Y Mao","year":"2017","unstructured":"Mao Y, Yan C, Lu Q, Zhu M, Yu F, Wang C, et al. Shen HJEJoHG: Genetically predicted high body mass index is associated with increased gastric cancer risk. 2017;25(9):1061\u20136.","journal-title":"Shen HJEJoHG: Genetically predicted high body mass index is associated with increased gastric cancer risk"},{"key":"16554_CR45","doi-asserted-by":"crossref","unstructured":"Shi X, Deng G, Wen H, Lin A, Wang H, Zhu L, Mou W, Liu Z, Li X, Zhang JJJogh: Role of body mass index and weight change in the risk of cancer: A systematic review and meta-analysis of 66 cohort studies. 2024, 14:04067.","DOI":"10.7189\/jogh.14.04067"},{"issue":"23","key":"16554_CR46","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343\u201351.","journal-title":"N Engl J Med"},{"issue":"16","key":"16554_CR47","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938\u201347.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16554_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23\u201330.","journal-title":"J Clin Oncol"},{"key":"16554_CR49","doi-asserted-by":"crossref","unstructured":"Morawska K, Goirand F, Marceau L, Devaux M: 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. 2018, 9(14):11559\u201311571.","DOI":"10.18632\/oncotarget.24338"},{"issue":"9","key":"16554_CR50","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1080\/07357900802132550","volume":"26","author":"S Sharif","year":"2008","unstructured":"Sharif S, O\u2019Connell MJ, Yothers G, Lopa S, Wolmark N. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 2008;26(9):956\u201363.","journal-title":"Cancer Invest"},{"key":"16554_CR51","doi-asserted-by":"crossref","unstructured":"Ta LE, Espeset L, Podratz J, Windebank AJJN: Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum\u2013DNA binding. 2006, 27(6):992\u20131002.","DOI":"10.1016\/j.neuro.2006.04.010"},{"issue":"4","key":"16554_CR52","first-page":"368","volume":"34","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E. Kalofonos HPJCtr: A review on oxaliplatin-induced peripheral nerve damage. 2008;34(4):368\u201377.","journal-title":"Kalofonos HPJCtr: A review on oxaliplatin-induced peripheral nerve damage"},{"issue":"3","key":"16554_CR53","volume":"6","author":"K Hodroj","year":"2021","unstructured":"Hodroj K, Barthelemy D, Lega J-C, Grenet G, Gagnieu M-C, Walter T. Guitton J. Payen-Gay LJEo: Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature. 2021;6(3):100125.","journal-title":"Payen-Gay LJEo: Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature"},{"issue":"9","key":"16554_CR54","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.6004\/jnccn.2017.7010","volume":"15","author":"Y Li","year":"2017","unstructured":"Li Y, Family L, Yang SJ, Klippel Z, Page JH, Chao C. Risk of febrile neutropenia associated with select myelosuppressive chemotherapy regimens in a large community-based oncology practice. JNCCN Journal of the National Comprehensive Cancer Network. 2017;15(9):1122\u201330.","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"issue":"11","key":"16554_CR55","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1080\/14737140.2017.1380521","volume":"17","author":"XZ Tan","year":"2017","unstructured":"Tan XZ, Wen QC, Wang R, Chen ZK. Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies. Expert Rev Anticancer Ther. 2017;17(11):1077\u201385.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"19","key":"16554_CR56","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andre","year":"2009","unstructured":"Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109\u201316.","journal-title":"J Clin Oncol"},{"key":"16554_CR57","first-page":"S415","volume":"2016","author":"I Wong","year":"2016","unstructured":"Wong I. Law SJTCR: The CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial. 2016;2016:S415\u20139.","journal-title":"Law SJTCR: The CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial"},{"issue":"4","key":"16554_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","volume":"101","author":"JW Valle","year":"2009","unstructured":"Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 2009;101(4):621\u20137.","journal-title":"Br J Cancer"},{"key":"16554_CR59","doi-asserted-by":"crossref","unstructured":"Smoragiewicz M, Javaheri KR, Yin Y, Gill S. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. Journal of gastrointestinal cancer. 2014;45(4):460\u20135.","DOI":"10.1007\/s12029-014-9639-2"},{"issue":"5","key":"16554_CR60","doi-asserted-by":"publisher","first-page":"841","DOI":"10.21037\/jgo.2019.07.03","volume":"10","author":"LG Kogan","year":"2019","unstructured":"Kogan LG, Davis SL, Brooks GA. Treatment delays during FOLFOX chemotherapy in patients with colorectal cancer: A multicenter retrospective analysis. Journal of Gastrointestinal Oncology. 2019;10(5):841\u20136.","journal-title":"Journal of Gastrointestinal Oncology"},{"key":"16554_CR61","doi-asserted-by":"crossref","unstructured":"Mitchell EP: Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol. 2006;33(1):106\u201320.","DOI":"10.1053\/j.seminoncol.2005.12.001"},{"key":"16554_CR62","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011322","author":"YF Tsai","year":"2018","unstructured":"Tsai YF, Huang WC, Cho SF, Hsiao HH, Liu YC, Lin SF, et al. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan. Medicine (Baltimore). 2018. https:\/\/doi.org\/10.1097\/MD.0000000000011322.","journal-title":"Medicine (Baltimore)"},{"key":"16554_CR63","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.2147\/OTT.S168418","volume":"11","author":"M Zeng","year":"2018","unstructured":"Zeng M, Feng Q, Lu M, Zhou J, Yang Z, Tang J. Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. OncoTargets Ther. 2018;11:6633\u201346.","journal-title":"OncoTargets Ther"},{"key":"16554_CR64","doi-asserted-by":"crossref","unstructured":"Smith SM, Wachter K, Burris III HA, Schilsky RL, George DJ, Peterson DE, Johnson ML, Markham MJ, Mileham KF, Beg MSJJoCO: Clinical cancer advances 2021: ASCO's report on progress against cancer. 2021, 39(10):1165\u20131184.","DOI":"10.1200\/JCO.20.03420"},{"issue":"10","key":"16554_CR65","first-page":"1375","volume":"4","author":"SB Johnson","year":"2018","unstructured":"Johnson SB, Park HS. Gross CP. Yu JBJJo: Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. 2018;4(10):1375\u201381.","journal-title":"Yu JBJJo: Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers"},{"key":"16554_CR66","doi-asserted-by":"crossref","unstructured":"Patel VG, Oh WK, Galsky MDJCacjfc: Treatment of muscle\u2010invasive and advanced bladder cancer in 2020. 2020, 70(5):404\u2013423.","DOI":"10.3322\/caac.21631"},{"key":"16554_CR67","doi-asserted-by":"crossref","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington DJJotNCCN: Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology. 2019, 17(3):255\u2013289.","DOI":"10.6004\/jnccn.2019.0013"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16554-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:56:31Z","timestamp":1792061791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16554-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16554"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16554-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for the study was obtained from the School of Pharmacy, College of Health Sciences, AAU, ethical review board with Ref no: ERB\/SOP\/522\/15\/2023 and also from the Institution Review Board (IRB) of SPHMMC with Ref no. PM 23\/212. Before data collection, written permission was obtained from the oncology units of TASH and SPHMMC. This study adhered to the Declaration of Helsinki. The aims of the study were clearly explained to the participants, and information was collected after obtaining written informed consent from each patient or their family. Patients were given the right to refuse or discontinue participation at any time and to ask questions about the study objective. To protect privacy, patients\u2019 names were not used during data collection, personal information was kept confidential, and confidentiality was maintained throughout the study period.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1230"}}